The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlethora Solutions Holdings Plc Regulatory News (PLE)

  • There is currently no data for PLE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Further Regarding General Meeting

2 Sep 2014 07:00

RNS Number : 5692Q
Plethora Solutions Holdings PLC
02 September 2014
 



 

 

2 September 2014

 

Plethora Solutions Holdings PLC

("Plethora" or the "Company")

 

Further Regarding General Meeting

 

 

Further to the announcement made on 29 August 2014, Plethora Solutions Holdings plc (AIM: PLE) announces that the Company has posted a new Notice of General Meeting to Shareholders, which is intended to be in substitution for that attached to the Circular letter dated 29 August 2014. The new Notice of General Meeting to Shareholders will be made available on the Company's website, www.plethorasolutions.co.uk.

 

Shareholders are advised to disregard the Notice of General Meeting, and accompanying proxy card, attached to the Circular Letter dated 29 August 2014. It is the intention of the Board that a resolution will be put to the meeting of shareholders already scheduled for 17 September 2014 pursuant to the notice dated 29 August 2014 resolving that the meeting will be adjourned sine die. Please note that the date of the replacement General Meeting has changed to 18 September 2014.

 

Shareholders will receive a new Notice of General Meeting and a replacement Form of Proxy for use at the replacement General Meeting to be held on 18 September 2014.

 

All terms defined in that letter dated Friday, 29 August 2014 have the same meaning when used in this announcement. Shareholders and investors should read the whole text of this announcement.

 

 

Background

 

The Chairman of the Company wrote to Shareholders on Friday, 29 August 2014 in order, inter alia, to convene a General Meeting of shareholders to pass the necessary shareholders resolutions to approve the matters referred to in that Circular letter.

 

Unfortunately, the Notice of General Meeting attached to that Circular letter contained some minor printing errors. Because the Notice of General Meeting is a formal document, it is necessary to issue a new Notice of General Meeting intended to be in substitution for that attached to the Circular letter dated 29 August 2014.

 

Accordingly, a new Notice of General Meeting in which the printing errors have been corrected together with a replacement proxy card for use in relation to the Notice of General Meeting has been sent to Shareholders.

 

Shareholders are advised to disregard the Notice of General Meeting, and accompanying proxy card, attached to the Circular Letter dated 29 August 2014. It is the intention of the Board that a resolution will be put to the meeting of shareholders already scheduled for 17 September 2014 pursuant to the notice dated 29 August 2014 resolving that the meeting will be adjourned sine die.

 

Please note that the date of the replacement General Meeting has changed to 18 September 2014.

 

 

Action to be Taken

 

Shareholders will receive a new Notice of General Meeting and a replacement Form of Proxy for use at the replacement General Meeting. Whether or not Shareholders intend to attend the replacement General Meeting Shareholders are requested to complete the replacement Form of Proxy in accordance with the instructions printed on it and to return it to the Company's registrars, Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA, as soon as possible, and in any event so as to arrive no later than 10:00am on 16 September 2014.

 

If Shareholders hold their Ordinary Shares in CREST they may appoint a proxy using the CREST proxy appointment service by following the instructions in note (6) to the replacement Notice of General Meeting. The completion and return of a Form of Proxy, or the electronic appointment of a proxy will not preclude Shareholders from attending the General Meeting and voting in person should they so wish.

 

 

Recommendation

 

The Directors believe that the Placing & Subscription, and therefore the Resolutions set out in the replacement Notice of General Meeting, are in the best interests of the Company and Shareholders taken as a whole. The Directors unanimously recommend that Shareholders vote in favour of those Resolutions, as they intend to do in respect of their own shareholdings, which in aggregate total 131,949,742 Ordinary Shares representing approximately 31.8% of the existing issued ordinary share capital of the Company.

 

-Ends-

 

Enquiries:

Plethora Solutions

Jim Mellon, Chairman

Jamie Gibson, CEO

Mike Wyllie, CSO

Mike Collis, CFO

Greg Bailey, NXD

 

Tel : +44(0) 20 3077 5400

Daniel Stewart (Nomad & Joint Broker)

Emma Earl / Alex Brearley (Nomad)

Martin Lampshire (Broker)

 

Tel : +44(0) 20 7776 6550

 

Hybridan LLP (Joint Broker)

Claire Louise Noyce

William Lynne

Niall Pearson

 

Tel: +44(0) 20 3713 4581

Tel: +44(0) 20 3713 4582

Tel: +44(0) 20 3713 4583

 

Britton Financial PR

Tim Blackstone

Tel: + 44 (0) 20 7242 9786

+44 (0) 7957 140416

 

About Plethora:

 

Plethora is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L). Further information is available at www.plethorasolutions.co.uk

Plethora is focussed on seeking to launch PSD502™ for the treatment of premature ejaculation.

 

About PSD502™ & Premature Ejaculation:

 

PSD502™ is a topical spray for the treatment of premature ejaculation containing lidocaine and prilocaine in a eutectic-like mixture. Premature ejaculation is possibly the most common form of sexual dysfunction in men. Epidemiological studies conducted in the US and in Europe indicate a prevalence of 20 - 30% in men of all ages. There is currently no globally approved and effective pharmaceutical treatment for this condition.

 

In the absence of any widely approved pharmaceutical therapy with good patient acceptance, the premature ejaculation market offers significant potential for development and growth. An effective drug therapy for premature ejaculation may have a comparable commercial potential to the erectile dysfunction drugs.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FURUAOURSVAKRUR
Date   Source Headline
18th Sep 201410:37 amRNSResult of General Meeting
17th Sep 201410:39 amRNSGeneral Meeting Update
16th Sep 20149:38 amRNSHolding(s) in Company
16th Sep 20148:00 amRNSLicensing Agreement signed with Recordati
8th Sep 20144:18 pmRNSIssue of Equity
2nd Sep 20147:00 amRNSFurther Regarding General Meeting
29th Aug 20144:21 pmRNSConditional Subscription to raise £2.3million
29th Aug 20142:37 pmRNSINTERIM RESULTS
29th Aug 20142:30 pmRNSFundraising and Notice of General Meeting
29th Aug 20142:30 pmRNSRestoration - Plethora Solutions Holdings plc
29th Aug 20148:00 amRNSSuspension - Plethora Solutions Holdings plc
10th Jun 201410:42 amRNSResult of AGM
19th May 20147:00 amRNSLoan repayment
7th May 201410:36 amRNSHolding(s) in Company
25th Apr 20145:00 pmRNSUpdated investor presentation
23rd Apr 20147:00 amRNSAnnual Financial Report and notice of AGM
22nd Apr 201410:49 amRNSPreliminary Results for the year ended 31 Dec 2013
26th Mar 20147:00 amRNSManufacturing Appointment
11th Mar 20148:12 amRNSCompany update
3rd Feb 20148:45 amRNSCompany update and Investor presentation
13th Jan 201410:57 amRNSHolding(s) in Company
20th Dec 20133:34 pmRNSCEO Appointment
18th Dec 201310:37 amRNSHolding(s) in Company
16th Dec 20134:52 pmRNSAward of LTIPs
29th Nov 20137:00 amRNSAward of LTIPs & Issue of Ordinary Shares
28th Nov 20137:01 amRNSConversion of Loan Notes
28th Nov 20137:00 amRNSResignation of CEO
22nd Nov 20137:00 amRNSCommercial Update
19th Nov 20137:00 amRNSEuropean Commission Approval
4th Nov 20139:40 amRNSHolding(s) in Company
4th Nov 20139:05 amRNSTotal Voting Rights
4th Nov 20137:00 amRNSHolding(s) in Company
31st Oct 201311:04 amRNSResult of GM
28th Oct 201311:10 amRNSHolding(s) in Company
16th Oct 201310:50 amRNSHolding(s) in Company
15th Oct 20133:16 pmRNSPlacing & Subscription to raise £4.4 million
15th Oct 20133:14 pmRNSExercise of warrant
30th Sep 20137:00 amRNSINTERIM RESULTS FOR SIX MONTHS ENDED 30 JUNE 2013
27th Sep 201312:11 pmRNSHolding(s) in Company
27th Sep 201312:06 pmRNSHolding(s) in Company
20th Sep 20131:13 pmRNSPositive CHMP Opinion
12th Sep 20137:00 amRNSBoard Changes
22nd Aug 20137:00 amRNSGlobal expansion of commercialisation of PSD502
1st Jul 201312:07 pmRNSAGM Statement & PSD502 Regulatory Update
18th Jun 20133:23 pmRNSNotice of Results and AGM
17th Jun 20131:21 pmRNSHolding(s) in Company
7th Jun 20137:00 amRNSPreliminary Results for the year ended 31 Dec 2012
12th Apr 201310:30 amRNSDirectorate Change
4th Apr 20132:17 pmRNSResult of GM
18th Mar 20131:09 pmRNSPlacing to raise £2.124m

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.